The ultimate objective of the research projects in this program project application is to improve the therapeutic results for patients with leukemia and lymphoma. To achieve this objective, results of laboratory studies will be used to provide the basis for development of new treatment approaches in the clinic. At the same time, tumor samples from patients at diagnosis and/or relapse and normal lymphocytes and other cells from patients enrolled on clinical trials are studied to assess the responses to new treatments. As a results, the clinical projects in particular require research resources which extend beyond direct patient care and clinical laboratory functions. Without clinical research support provided in this Core it would not be possible to coordinate the proper collection of multiple research specimens from hundreds of patients/year, as well as th timely follow up of patients enrolled on research studies. Equally important for the success of the project is the collaboration of individuals in this core with staff from the biostatistic Core, who provide a quality control system for specimen tracking, computerized data entry, quality control of data as well as assist in the design and analysis of clinical research protocols. The purpose of the Clinical Research Support Core is to provide the following services that will be utilized by all of the research projects. 1. To collect research specimens and coordinate patient follow-up at DFCI and affiliated hospitals. 2. Act as liaison with outside physician and hospitals to coordinate the collection of research specimens and follow-up data. 3. To ensure that study parameters are followed, confirm eligibility and patient registration. 4. Ensure that study parameters are followed, confirm eligibility and patient registration. 4. Ensure accuracy of submitted data from outside sources. 5. To provide data management for the collection of individual patient information.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA066996-05
Application #
6314046
Study Section
Project Start
2000-05-10
Project End
2002-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
5
Fiscal Year
2000
Total Cost
$226,134
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
DiNardo, Courtney D; Pratz, Keith W; Letai, Anthony et al. (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19:216-228
Brien, Gerard L; Remillard, David; Shi, Junwei et al. (2018) Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife 7:
Weinberg, Olga K; Gibson, Christopher J; Blonquist, Traci M et al. (2018) Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. Haematologica 103:626-633
Hoshii, Takayuki; Cifani, Paolo; Feng, Zhaohui et al. (2018) A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response. Cell 172:1007-1021.e17
Gutierrez-Martinez, Paula; Hogdal, Leah; Nagai, Manavi et al. (2018) Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage. Nat Cell Biol 20:413-421
Gooptu, Mahasweta; Kim, Haesook T; Chen, Yi-Bin et al. (2018) Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. Biol Blood Marrow Transplant 24:2216-2223
Kleppe, Maria; Koche, Richard; Zou, Lihua et al. (2018) Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell 33:29-43.e7
Nabet, Behnam; Roberts, Justin M; Buckley, Dennis L et al. (2018) The dTAG system for immediate and target-specific protein degradation. Nat Chem Biol 14:431-441
Ebert, Benjamin L; Krönke, Jan (2018) Inhibition of Casein Kinase 1 Alpha in Acute Myeloid Leukemia. N Engl J Med 379:1873-1874
List, Alan; Ebert, Benjamin L; Fenaux, Pierre (2018) A decade of progress in myelodysplastic syndrome with chromosome 5q deletion. Leukemia 32:1493-1499

Showing the most recent 10 out of 376 publications